Precision Medicine Using Pharmacogenomic Panel-Testing Current Status and Future Perspectives

被引：3
作者：
van der Wouden, Cathelijne H. [1 ,2 ]
Guchelaar, Henk-Jan [1 ,2 ]
Swen, Jesse J. [1 ,2 ]
机构：
[1] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[2] Leiden Network Personalised Therapeut, Leiden, Netherlands
来源：
CLINICS IN LABORATORY MEDICINE | 2022年 / 42卷 / 04期
关键词：
Pharmacogenomics; Panel-testing; Implementation; Adverse drug reactions; DNA REFERENCE MATERIALS; PERSONALIZED MEDICINE; IMPLEMENTING PHARMACOGENOMICS; CLINICAL IMPLEMENTATION; DECISION-SUPPORT; RANDOMIZED-TRIAL; GENOMICS; VARIANTS; CYP2D6; BENCH;
D O I：
10.1016/j.cll.2022.09.012
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
[No abstract available]
引用
收藏
页码：587 / 602
页数：16
相关论文
共 105 条
  • [41] Useless Until Proven Effective: The Clinical Utility of Preemptive Pharmacogenetic Testing
    Janssens, A. C. J. W.
    Deverka, P. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (06) : 652 - 654
  • [42] DRUG-RELATED MORBIDITY AND MORTALITY - A COST-OF-ILLNESS MODEL
    JOHNSON, JA
    BOOTMAN, JL
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (18) : 1949 - 1956
  • [43] Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine
    Kaddurah-Daouk, R.
    Weinshilboum, R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (01) : 71 - 75
  • [44] Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics
    Kalia, Sarah S.
    Adelman, Kathy
    Bale, Sherri J.
    Chung, Wendy K.
    Eng, Christine
    Evans, James P.
    Herman, Gail E.
    Hufnagel, Sophia B.
    Klein, Teri E.
    Korf, Bruce R.
    McKelvey, Kent D.
    Ormond, Kelly E.
    Richards, C. Sue
    Vlangos, Christopher N.
    Watson, Michael
    Martin, Christa L.
    Miller, David T.
    [J]. GENETICS IN MEDICINE, 2017, 19 (02) : 249 - 255
  • [45] Dealing With the Evidence Dilemma in Genomics and Personalized Medicine
    Khoury, M. J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (06) : 635 - 638
  • [46] Comparative effectiveness research and genomic medicine: An evolving partnership for 21st century medicine
    Khoury, Muin J.
    Rich, Eugene C.
    Randhawa, Gurvaneet
    Teutsch, Steven M.
    Niederhuber, John
    [J]. GENETICS IN MEDICINE, 2009, 11 (10) : 707 - 711
  • [47] Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response
    Kozyra, Mikael
    Ingelman-Sundberg, Magnus
    Lauschke, Volker M.
    [J]. GENETICS IN MEDICINE, 2017, 19 (01) : 20 - 29
  • [48] Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity
    Lauschke, Volker M.
    Zhou, Yitian
    Ingelman-Sundberg, Magnus
    [J]. PHARMACOLOGY & THERAPEUTICS, 2019, 197 : 122 - 152
  • [49] How to Consider Rare Genetic Variants in Personalized Drug Therapy
    Lauschke, Volker M.
    Ingelman-Sundberg, Magnus
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (05) : 745 - 748
  • [50] Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu
    Leitsalu, Liis
    Haller, Toomas
    Esko, Tonu
    Tammesoo, Mari-Liis
    Alavere, Helene
    Snieder, Harold
    Perola, Markus
    Ng, Pauline C.
    Maegi, Reedik
    Milani, Lili
    Fischer, Krista
    Metspalu, Andres
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2015, 44 (04) : 1137 - 1147
12345678910